Rockwell Medical traded at $2.05 this Wednesday August 17th, decreasing $0.01 or 0.49 percent since the previous trading session. Looking back, over the last four weeks, Rockwell Medical lost 71.29 percent. Over the last 12 months, its price rose by 241.67 percent. Looking ahead, we forecast Rockwell Medical to be priced at 1.79 by the end of this quarter and at 1.64 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Abbott 110.55 -1.48 -1.32% -12.07%
Atrion 631.18 -13.95 -2.16% -5.29%
Avanos Medical Inc 27.46 -0.92 -3.24% -18.20%
Baxter International 61.38 -0.46 -0.74% -18.45%
Cerus 4.88 -0.16 -3.17% -16.44%
Fresenius Medical Care 36.55 0.32 0.88% -46.67%
Fresenius Medical Care 18.39 -0.58 -3.06% -54.59%
Haemonetics 75.96 -0.36 -0.47% 29.58%
Merit Medical Systems 62.01 -1.31 -2.07% -7.50%
Neogen 21.43 -0.50 -2.28% -49.56%
Omeros 6.63 0.09 1.38% -54.37%
OraSure Technologies 4.30 -0.10 -2.27% -57.97%
Quidel 85.66 -3.08 -3.47% -27.44%
Rockwell Medical 2.05 -0.01 -0.49% 241.67%
Sanofi 81.77 0.10 0.12% -9.32%
Sientra 0.98 -0.02 -1.99% -84.34%
STAAR Surgical 100.63 -1.40 -1.37% -29.97%
Utah Medical Products 93.20 -1.32 -1.40% 6.60%
Meridian Bioscience 32.92 -0.08 -0.24% 68.99%

Indexes Price Day Year
USND 12938 -164.43 -1.25% -10.93%
US2000 1987 -33.22 -1.64% -7.94%

Rockwell Medical
Rockwell Medical, Inc. is a commercial-stage, biopharmaceutical company. The Company is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. It is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The Company has developed therapies namely Triferic and Triferic AVNU from its FPC platform. The Company’s products from its FPC platform, Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. its dialysis concentrates products include CitraPure Citric Acid Concentrate, Dri-Sate Dry Acid Concentrate, RenalPure Liquid Acid Concentrate, Dry Acid Concentrate Mixer, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.